2seventy bio Inc (TSVT)
4.90
+0.17
(+3.59%)
USD |
NASDAQ |
May 15, 14:28
2seventy bio Enterprise Value: 61.77M for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 61.77M |
| May 13, 2024 | 49.43M |
| May 10, 2024 | 43.77M |
| May 09, 2024 | 46.60M |
| May 08, 2024 | 48.91M |
| May 07, 2024 | 73.59M |
| May 06, 2024 | 73.07M |
| May 03, 2024 | 63.31M |
| May 02, 2024 | 72.04M |
| May 01, 2024 | 55.08M |
| April 30, 2024 | 53.02M |
| April 29, 2024 | 54.57M |
| April 26, 2024 | 37.35M |
| April 25, 2024 | 39.14M |
| April 24, 2024 | 38.12M |
| April 23, 2024 | 56.62M |
| April 22, 2024 | 57.65M |
| April 19, 2024 | 50.97M |
| April 18, 2024 | 57.14M |
| April 17, 2024 | 78.73M |
| April 16, 2024 | 68.45M |
| April 15, 2024 | 74.87M |
| April 12, 2024 | 77.69M |
| April 11, 2024 | 102.37M |
| April 10, 2024 | 87.46M |
| Date | Value |
|---|---|
| April 09, 2024 | 108.02M |
| April 08, 2024 | 101.85M |
| April 05, 2024 | 71.53M |
| April 04, 2024 | 76.15M |
| April 03, 2024 | 74.61M |
| April 02, 2024 | 72.55M |
| April 01, 2024 | 116.25M |
| March 31, 2024 | 93.63M |
| March 28, 2024 | 57.53M |
| March 27, 2024 | 59.06M |
| March 26, 2024 | 37.51M |
| March 25, 2024 | 34.44M |
| March 22, 2024 | 46.24M |
| March 21, 2024 | 39.05M |
| March 20, 2024 | 15.96M |
| March 19, 2024 | 13.40M |
| March 18, 2024 | -1.996M |
| March 15, 2024 | -11.24M |
| March 14, 2024 | -13.80M |
| March 13, 2024 | -11.23M |
| March 12, 2024 | 25.71M |
| March 11, 2024 | 18.02M |
| March 08, 2024 | 25.20M |
| March 07, 2024 | 59.06M |
| March 06, 2024 | 73.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-171.14M
Minimum
Nov 21 2023
994.59M
Maximum
Nov 09 2021
158.40M
Average
144.11M
Median
Jul 01 2022
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 136.70B |
| Johnson & Johnson | 371.74B |
| Macrogenics Inc | 94.48M |
| Akebia Therapeutics Inc | 245.99M |
| Tango Therapeutics Inc | 468.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.67M |
| Revenue (Quarterly) | 12.44M |
| Total Expenses (Quarterly) | 61.09M |
| EPS Diluted (Quarterly) | -1.01 |
| Gross Profit Margin (Quarterly) | 63.82% |
| Profit Margin (Quarterly) | -423.6% |
| Earnings Yield | -88.78% |
| Normalized Earnings Yield | -77.52 |